FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136125059> ?p ?o ?g. }

• W3136125059 endingPage "1045" @default.
• W3136125059 startingPage "1038" @default.
• W3136125059 abstract "Cerebral amyloid angiopathy (CAA) is a known risk factor for ischemic stroke though angiographic imaging is often negative. Our goal was to determine the relationship between vessel wall enhancement (VWE) in acute and future ischemic stroke in CAA patients.This was a retrospective study of patients with new-onset neurologic symptoms undergoing 3T vessel wall MR imaging from 2015 to 2019. Vessel wall enhancement was detected on pre- and postcontrast flow-suppressed 3D T1WI. Interrater agreement was evaluated in cerebral amyloid angiopathy-positive and age-matched negative participants using a prevalence- and bias-adjusted kappa analysis. In patients with cerebral amyloid angiopathy, multivariable Poisson and Cox regression were used to determine the association of vessel wall enhancement with acute and future ischemic stroke, respectively, using backward elimination of confounders to P < .20.Fifty patients with cerebral amyloid angiopathy underwent vessel wall MR imaging, including 35/50 (70.0%) with ischemic stroke and 29/50 (58.0%) with vessel wall enhancement. Prevalence- and bias-corrected kappa was 0.82 (95% CI, 0.71-0.93). The final regression model for acute ischemic stroke included vessel wall enhancement (prevalence ratio = 1.5; 95% CI, 1.1-2.2; P = .022), age (prevalence ratio = 1.02; 95% CI, 1.0-1.05; P = .036), time between symptoms and MR imaging (prevalence ratio = 0.9; 95% CI, 0.8-0.9; P < .001), and smoking (prevalence ratio = 0.7; 95% CI, 0.5-1.0; P = .042) with c-statistic = 0.92 (95% CI, 0.84-0.99). Future ischemic stroke incidence with cerebral amyloid angiopathy was 49.7% (95% CI, 34.5%-67.2%) per year over a total time at risk of 37.5 person-years. Vessel wall enhancement-positive patients with cerebral amyloid angiopathy demonstrated significantly shorter stroke-free survival with 63.9% (95% CI, 43.2%-84.0%) versus 32.2% (95% CI, 14.4%-62.3%) ischemic strokes per year, chi-square = 4.9, P = .027. The final model for future ischemic stroke had a c-statistic of 0.70 and included initial ischemic stroke (hazard ratio = 3.4; 95% CI, 1.0-12.0; P = .053) and vessel wall enhancement (hazard ratio = 2.5; 95% CI, 0.9-7.0; P = .080).Vessel wall enhancement is associated with both acute and future stroke in patients with cerebral amyloid angiopathy." @default.
• W3136125059 created "2021-03-29" @default.
• W3136125059 creator A5011157468 @default.
• W3136125059 creator A5020567240 @default.
• W3136125059 creator A5030638248 @default.
• W3136125059 creator A5054427080 @default.
• W3136125059 creator A5057523173 @default.
• W3136125059 creator A5064269428 @default.
• W3136125059 creator A5064804226 @default.
• W3136125059 creator A5084878730 @default.
• W3136125059 creator A5087567831 @default.
• W3136125059 date "2021-03-18" @default.
• W3136125059 modified "2023-10-17" @default.
• W3136125059 title "Vessel Wall Enhancement on Black-Blood MRI Predicts Acute and Future Stroke in Cerebral Amyloid Angiopathy" @default.
• W3136125059 cites W1970999274 @default.
• W3136125059 cites W1976789551 @default.
• W3136125059 cites W1987751736 @default.
• W3136125059 cites W1996093516 @default.
• W3136125059 cites W1997609035 @default.
• W3136125059 cites W2005257697 @default.
• W3136125059 cites W2007878973 @default.
• W3136125059 cites W2038135574 @default.
• W3136125059 cites W2061820841 @default.
• W3136125059 cites W2070857646 @default.
• W3136125059 cites W2087371306 @default.
• W3136125059 cites W2087529125 @default.
• W3136125059 cites W2122843800 @default.
• W3136125059 cites W2123199210 @default.
• W3136125059 cites W2130373985 @default.
• W3136125059 cites W2138244817 @default.
• W3136125059 cites W2142555588 @default.
• W3136125059 cites W2163480552 @default.
• W3136125059 cites W2163674007 @default.
• W3136125059 cites W2164300497 @default.
• W3136125059 cites W2168049667 @default.
• W3136125059 cites W2168094470 @default.
• W3136125059 cites W2307386694 @default.
• W3136125059 cites W2344353791 @default.
• W3136125059 cites W2355524658 @default.
• W3136125059 cites W2415891810 @default.
• W3136125059 cites W2496719711 @default.
• W3136125059 cites W2511967474 @default.
• W3136125059 cites W2517459219 @default.
• W3136125059 cites W2521664509 @default.
• W3136125059 cites W2756559761 @default.
• W3136125059 cites W2766433096 @default.
• W3136125059 cites W2789907674 @default.
• W3136125059 cites W2909270098 @default.
• W3136125059 cites W2914327648 @default.
• W3136125059 cites W3006792038 @default.
• W3136125059 cites W3010594541 @default.
• W3136125059 doi "https://doi.org/10.3174/ajnr.a7047" @default.
• W3136125059 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8191668" @default.
• W3136125059 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33737266" @default.
• W3136125059 hasPublicationYear "2021" @default.
• W3136125059 type Work @default.
• W3136125059 sameAs 3136125059 @default.
• W3136125059 citedByCount "5" @default.
• W3136125059 countsByYear W31361250592021 @default.
• W3136125059 countsByYear W31361250592022 @default.
• W3136125059 countsByYear W31361250592023 @default.
• W3136125059 crossrefType "journal-article" @default.
• W3136125059 hasAuthorship W3136125059A5011157468 @default.
• W3136125059 hasAuthorship W3136125059A5020567240 @default.
• W3136125059 hasAuthorship W3136125059A5030638248 @default.
• W3136125059 hasAuthorship W3136125059A5054427080 @default.
• W3136125059 hasAuthorship W3136125059A5057523173 @default.
• W3136125059 hasAuthorship W3136125059A5064269428 @default.
• W3136125059 hasAuthorship W3136125059A5064804226 @default.
• W3136125059 hasAuthorship W3136125059A5084878730 @default.
• W3136125059 hasAuthorship W3136125059A5087567831 @default.
• W3136125059 hasBestOaLocation W31361250591 @default.
• W3136125059 hasConcept C126322002 @default.
• W3136125059 hasConcept C126838900 @default.
• W3136125059 hasConcept C127413603 @default.
• W3136125059 hasConcept C134018914 @default.
• W3136125059 hasConcept C143409427 @default.
• W3136125059 hasConcept C164705383 @default.
• W3136125059 hasConcept C2777790613 @default.
• W3136125059 hasConcept C2779134260 @default.
• W3136125059 hasConcept C2779483572 @default.
• W3136125059 hasConcept C2779703115 @default.
• W3136125059 hasConcept C2780645631 @default.
• W3136125059 hasConcept C50382708 @default.
• W3136125059 hasConcept C555293320 @default.
• W3136125059 hasConcept C71924100 @default.
• W3136125059 hasConcept C77350462 @default.
• W3136125059 hasConcept C78519656 @default.
• W3136125059 hasConceptScore W3136125059C126322002 @default.
• W3136125059 hasConceptScore W3136125059C126838900 @default.
• W3136125059 hasConceptScore W3136125059C127413603 @default.
• W3136125059 hasConceptScore W3136125059C134018914 @default.
• W3136125059 hasConceptScore W3136125059C143409427 @default.
• W3136125059 hasConceptScore W3136125059C164705383 @default.
• W3136125059 hasConceptScore W3136125059C2777790613 @default.
• W3136125059 hasConceptScore W3136125059C2779134260 @default.
• W3136125059 hasConceptScore W3136125059C2779483572 @default.
• W3136125059 hasConceptScore W3136125059C2779703115 @default.

• next